| View printer-friendly version|
|MyoKardia to Host R&D Day on September 21|
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2016 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, will host a Research and Development (R&D) Day for analysts and investors on Sept. 21, 2016, at 8:30 a.m. ET in New York City.
During the R&D day, presentations by members of MyoKardia’s management team and guest speakers will include:
- MyoKardia Vision 2020
Tassos Gianakakos, Chief Executive Officer
- MyoKardia’s Scientific Foundation
Christine Seidman, M.D., Co-Founder of MyoKardia
Professor of Genetics and the Thomas W. Smith Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital
- An Overview of Hypertrophic Cardiomyopathy
Srihari Naidu, M.D.
Director, Cardiac Catheterization Laboratory, Interventional Cardiology Fellowship Program and HCM Treatment Center at Winthrop University Hospital
- MYK-461 Phase 1 Studies in Hypertrophic Cardiomyopathy
Andrew Wang, M.D.
Professor, Duke University School of Medicine
- MYK-461 and the Path to Registration
Jonathan Fox, M.D., Ph.D., Chief Medical Officer
- An Overview of Dilated Cardiomyopathy
Daniel Judge, M.D.
Associate Professor of Medicine, Johns Hopkins University School of Medicine; Medical Director, Center for Inherited Heart Disease
- MyoKardia’s Dilated Cardiomyopathy Program: MYK-491
Robert McDowell, Ph.D., SVP of Drug Discovery
- Research Directions Toward Vision 2020
Michael Graziano, Ph.D., VP, Research Biology
To access the live webcast of MyoKardia’s R&D Day presentation, please visit the “Events & Presentations” page within the Investors & Media section of the MyoKardia website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 30 days following the event.
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases. MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM. MyoKardia’s most advanced product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM and is currently being evaluated in three Phase 1 clinical trials. A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry, or SHaRe, a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia believes that SHaRe, currently consisting of data from approximately 10,000 individuals, is the world’s largest registry of patients with heritable cardiomyopathies. MyoKardia’s purpose is to improve the lives of patients and families suffering from cardiovascular disease by creating targeted therapies that can change the course of their condition. For more information, please visit www.myokardia.com.
Stern Investor Relations, Inc.